Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CING
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
newsfilecorp.com
8 hours ago
globenewswire.com
9 hours ago
newsfilecorp.com
16 hours ago
Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-72.03
vs -86.43
Q4.23
N/A
-7.66
vs -98.44
Q1.24
N/A
-7.20
vs -84.03
Q2.24
N/A
-5.47
vs -136.85
Q3.24
N/A
-1.83
vs -72.03
Q4.24
N/A
-0.14
vs -7.66
Q1.25
N/A
-1.04
vs -7.20
Q2.25
N/A
-1.09
vs -5.47
Q3.25
N/A
-0.88
vs -1.83
Q4.25
N/A
-0.78
vs -0.14
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
-3849997128.00 vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
+437%
13B vs -3849997128
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-4907%
-49.07
vs 0.01
Q2.23
+108%
1.08
vs -49.07
Q3.23
+6207%
62.07
vs 1.08
Q4.23
+101%
1.01
vs 62.07
Q1.24
-92%
-0.92
vs 1.01
Q2.24
-104%
-1.04
vs -0.92
Q3.24
-27%
-0.27
vs -1.04
Q4.24
-82%
-0.82
vs -0.27
Q1.25
-64%
-0.64
vs -0.82
Q2.25
-87%
-0.87
vs -0.64
Institutionnal Ownership
QoQ
Q2.21
NA
NA
vs NA
NA
Q3.21
NA
NA
vs NA
NA
Q4.21
5
5
vs NA
NA
Q1.22
5
5
vs 5
NA
Q2.22
7
7
vs 5
40%
Q3.22
6
6
vs 7
-14%
Q4.22
11
11
vs 6
83%
Q1.23
13
13
vs 11
18%
Q2.23
14
14
vs 13
8%
Q3.23
19
19
vs 14
36%
Forecast
2026-Revenue
-139%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Maxim Group
upgradePrevious: Not converted
2024-11-20
Now: Buy
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
NASDAQ
Unprofitable
Unprofitable
-0.23 ( -5.85%)
Pre-market 3.86$
0.16 (4.32%)
Relative Strenght
8
Volume Buzz
262%
Earning Acce
No
Dist 52w H.
38%Relative Strength
CING
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|